Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Shares Bought by Sumitomo Mitsui DS Asset Management Company Ltd

Sumitomo Mitsui DS Asset Management Company Ltd raised its position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 7.5% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 8,997 shares of the company’s stock after buying an additional 628 shares during the period. Sumitomo Mitsui DS Asset Management Company Ltd’s holdings in Neurocrine Biosciences were worth $1,185,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of NBIX. Headinvest LLC acquired a new position in shares of Neurocrine Biosciences during the 3rd quarter worth approximately $28,000. Lindbrook Capital LLC boosted its holdings in shares of Neurocrine Biosciences by 85.0% during the 4th quarter. Lindbrook Capital LLC now owns 209 shares of the company’s stock worth $28,000 after purchasing an additional 96 shares during the last quarter. BluePath Capital Management LLC acquired a new position in shares of Neurocrine Biosciences during the 3rd quarter worth approximately $35,000. Sunbelt Securities Inc. boosted its holdings in shares of Neurocrine Biosciences by 34.3% during the 3rd quarter. Sunbelt Securities Inc. now owns 325 shares of the company’s stock worth $37,000 after purchasing an additional 83 shares during the last quarter. Finally, Fifth Third Bancorp boosted its holdings in shares of Neurocrine Biosciences by 51.3% during the 3rd quarter. Fifth Third Bancorp now owns 622 shares of the company’s stock worth $70,000 after purchasing an additional 211 shares during the last quarter. 92.59% of the stock is currently owned by institutional investors and hedge funds.

Neurocrine Biosciences Trading Down 0.9 %

Neurocrine Biosciences stock opened at $137.76 on Friday. Neurocrine Biosciences, Inc. has a twelve month low of $89.04 and a twelve month high of $148.37. The stock’s fifty day simple moving average is $136.56 and its 200-day simple moving average is $127.69. The firm has a market capitalization of $13.71 billion, a P/E ratio of 56.93 and a beta of 0.25.

Neurocrine Biosciences (NASDAQ:NBIX) last issued its earnings results on Wednesday, February 7th. The company reported $1.44 EPS for the quarter, topping analysts’ consensus estimates of $1.13 by $0.31. The firm had revenue of $515.20 million during the quarter, compared to the consensus estimate of $518.52 million. Neurocrine Biosciences had a net margin of 13.23% and a return on equity of 12.85%. The company’s revenue was up 25.0% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.88 earnings per share. Sell-side analysts predict that Neurocrine Biosciences, Inc. will post 4.84 earnings per share for the current year.

Insider Buying and Selling

In related news, Director Richard F. Pops sold 15,000 shares of the business’s stock in a transaction on Tuesday, February 20th. The shares were sold at an average price of $132.47, for a total transaction of $1,987,050.00. Following the completion of the transaction, the director now owns 29,512 shares in the company, valued at $3,909,454.64. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In related news, Director Richard F. Pops sold 15,000 shares of the business’s stock in a transaction on Tuesday, February 20th. The shares were sold at an average price of $132.47, for a total transaction of $1,987,050.00. Following the completion of the transaction, the director now owns 29,512 shares in the company, valued at $3,909,454.64. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, insider Eric Benevich sold 19,818 shares of the business’s stock in a transaction on Monday, April 15th. The stock was sold at an average price of $133.36, for a total transaction of $2,642,928.48. Following the transaction, the insider now owns 40,778 shares of the company’s stock, valued at approximately $5,438,154.08. The disclosure for this sale can be found here. Over the last quarter, insiders sold 186,994 shares of company stock worth $25,806,409. Corporate insiders own 4.40% of the company’s stock.

Wall Street Analyst Weigh In

NBIX has been the topic of several recent research reports. JPMorgan Chase & Co. boosted their target price on Neurocrine Biosciences from $148.00 to $158.00 and gave the stock an “overweight” rating in a report on Wednesday, March 20th. HC Wainwright restated a “buy” rating and set a $150.00 target price on shares of Neurocrine Biosciences in a report on Wednesday. Wedbush reaffirmed an “outperform” rating and set a $147.00 price target on shares of Neurocrine Biosciences in a research report on Wednesday, April 17th. Mizuho lifted their price target on shares of Neurocrine Biosciences from $116.00 to $140.00 and gave the company a “neutral” rating in a research report on Thursday, February 8th. Finally, Oppenheimer reaffirmed an “outperform” rating and set a $200.00 price target on shares of Neurocrine Biosciences in a research report on Wednesday. Six analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $142.38.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.